SynapDx Licenses Gene Expression Technology from Children's Hospital Boston | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Startup SynapDx said today it has licensed technology from Children's Hospital Boston for the development of blood-based tests for the early detection of autism spectrum disorders.

Citing statistics from the Centers for Disease Control, SynapDx said about one in every 110 children in the US has the disorder.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic link between birth weight and adult-onset diseases, and more.

Even with all the current enthusiasm for gene therapies, Tech Review cautions that they are mostly in the early stages of development.

DNA phenotyping puts a potential face to a suspect in a nearly 25-year-old murder, the AP reports.

Researchers discuss the need for antibody standards at a meeting, NPR reports.